Clinical Trial Update: Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial investigating nilotinib in Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase patients with low imatinib trough…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Myelogenous Leukemia Chronic Phase
• Philadelphia Chromosome-positive Leukemia

Drugs mentioned

• Imatinib (imatinib)
• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: CML, Philadelphia Chromosome Positive (Ph+) | Phase 4 | Status: TERMINATED | Results posted: 2021-05-20